Clinical Trial Update: A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating repeated-dose hydromorphone hydrochloride (OROS formulation) for chronic cancer pain, focusing on safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Hydromorphone HCl (OROS formulation) (hydromorphone hydrochloride)

Snippet

Sponsor: Alza Corporation, DE, USA | Conditions: Analgesics, Opioid, Pain | Phase 3 | Status: COMPLETED